Management remarks
Call period: 2026 Q2 · 2026-07-29
Guidance: Jonathan Monson: Under current legislation, including enacted laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximately 11.5%. We expect full year 2026 adjusted earnings per share to be in a range of $3.28 to $3.32, representing 7% to 8% growth versus 2025, including an approximate $0.05 headwind from foreign exchange.Demand and orders: Michael Mahoney: And finally, we're accelerating direct-to-patient investments to stimulate demand, increase patient activation and reach more patients in the state of care journey -- in the start of care journey.Margins: Jonathan Monson: Adjusted gross margin for the second quarter was 70.3%, which represented an 80 basis point increase versus the second quarter of 2025.Analyst Q&A
Analyst Frederick Wise asked: I have 2 questions. First -- my first question is, I was hoping you could expand on your restructuring comments. We all read the release, the 8-K earlier this week. And you spoke about the -- some of the benefits and the efficiencies in the time frame. But could you talk a little bit more about the impact as we think about the next several years on the P&L? Management Jonathan Monson answered: So comprehensive enterprise-wide program that we're initiating. So goal of driving better speed and cost efficiency, targeting $500 million of savings within the next 3 years. Based off of the phasing of that program, we'd expect to realize over half of those savings exiting 2027. So we'll start to see those savings come in, in 2027.管理层陈述
电话会期间：2026 Q2 · 2026-07-29
指引：乔纳森·蒙森表示：根据现行立法（包括已颁布的法律和发布的指引），我们预计2026年全年调整后税率约为11.5%。我们预计2026年全年调整后每股收益区间为3.28美元至3.32美元，较2025年增长7%至8%，其中包含约0.05美元的外汇逆风因素。需求与订单：迈克尔·马奥尼表示：最后，我们将加快直接面向患者的投资，以刺激需求、提高患者活跃度，并在护理旅程的初始阶段接触更多患者。利润率：乔纳森·蒙森表示：第二季度调整后毛利率为70.3%，较2025年第二季度上升80个基点。分析师问答
分析师弗雷德里克·怀斯：我有两个问题，第一个是希望详细说明一下重组相关评论，我们都看了本周早些时候的8-K公告，也了解了部分效益和时间框架，能否多谈谈未来几年对损益表的影响？ 管理乔纳森·蒙森：我们正在启动全面的企业级项目，目标在未来3年内节省5亿美元以提升运营速度和成本效率，预计到2027年底将实现超过一半的节省额，2027年开始看到相关节省落地。This earnings research was prepared from company results, regulatory filings, financial statements, and earnings-call transcripts or official replays. It is for informational purposes only and does not constitute investment advice.这篇财报研究基于公司业绩公告、监管文件、财务报表，以及财报电话会议记录或官方回放整理。内容仅供参考，不构成投资建议。
